Events2Join
Ventus Therapeutics Nominates Potential First|in|Class cGAS ...

Ventus Therapeutics Nominates Potential First|in|Class cGAS ...

Ventus Therapeutics Nominates Potential First-in-Class cGAS ...

The nomination of VENT-03 as our first development candidate targeting cGAS was made possible by the unique insights provided by ReSOLVE, our proprietary drug ...

VENT-03, a First-in-Class cGAS Inhibitor - Ventus Therapeutics

Ventus Therapeutics Hosts Inaugural Program Spotlight: VENT-03, a First-in-Class cGAS Inhibitor ... WALTHAM, Mass. ... The virtual event will ...

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in ...

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor · WALTHAM, Mass. & MONTREAL — ...

Ventus Therapeutics Announces Successful Completion of Phase 1 ...

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor.

Ventus Therapeutics Provides Updates on cGAS Inhibitor Program ...

Ventus' portfolio of cGAS inhibitors have demonstrated modulation of key endpoints in models of lupus, dermal inflammation, and chronic kidney disease.

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in ...

"cGAS has historically proven an elusive target despite significant industry efforts to develop a viable inhibitor. We have broken that cycle ...

Ventus Therapeutics Nominates Potential First-in-Class ... - LinkedIn

Congrats to Ventus Therapeutics on a fantastic 2022 and even more exciting 2023, advancing the cGas program to the clinic. Like · Reply · 3 ...

Latest News - Ventus Therapeutics

Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise · December 1, 2022. Ventus ...

Ventus Therapeutics selects potential first-in-class cGAS inhibitor as ...

Ventus Therapeutics Inc. has nominated a potential first-in-class cyclic GMP-AMP synthase (cGAS) inhibitor, VENT-03, as the company's first ...

Ventus Therapeutics Nominates Potential First-in-Class cGAS ... - Gale

ENPNewswire-January 5, 2023--Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS ...

Ventus Begins Phase 1 Trial for VENT-03 cGAS Inhibitor

Ventus Therapeutics, a biopharmaceutical firm at the forefront of clinical-stage research, has initiated a Phase 1 clinical trial for VENT-03.

Dolca Thomas, MD on LinkedIn: Ventus Therapeutics Nominates ...

Dolca Thomas, MD's Post · Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in ...

VENT-03 / Ventus Therap - LARVOL DELTA

... potential first-in-class cGAS inhibitor, VENT-03. Ventus' portfolio of ... Delicious. January 04, 2023. Ventus Therapeutics Nominates Potential First-in ...

Ventus Therapeutics - FirstWord Pharma

... First-in-Class, Orally Administered cGAS Inhibitor. Ref: Business Wire ... Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural ...

Overview | Ventus Therapeutics

We screened our first target in 2020 and nominated three development candidates in 2022: VENT-03, a potential first-in-class cGAS inhibitor; VENT-02, a ...

Ventus Therapeutics Named a “Fierce 15” Biotech Company of 2023

In addition to VENT-02, Ventus is also rapidly advancing its first-in-class cGAS inhibitor, VENT-03, towards the clinic for development in lupus ...

Ventus-Therapeutics-Nominates-Potential-FirstinClass-cGAS ...

https://www.businesswire.com/news/home/20230417005140/en/Ventus-Therapeutics-Provides-Updates-on-cGAS-Inhibitor-Program-at-Keystone-Symposium-on-Innate- ...

Latest News | Ventus Therapeutics

Ventus Therapeutics Hosts Inaugural Program Spotlight: VENT-03, a First-in-Class cGAS Inhibitor · Ventus Therapeutics Awarded Grant by The Michael J. · Ventus ...

Ventus Therapeutics nominates brain-penetrant NLRP3 inhibitor as ...

Ventus Therapeutics Inc. is advancing its novel NLRP3 inhibitor programs and announced the recent nomination of VENT-02 as the company's ...

Ventus Therapeutics company information, funding & investors | EIT ...

Recent News about Ventus Therapeutics · Ventus Therapeutics Awarded Grant by The Michael J. · Ventus Therapeutics Nominates Potential First-In-Class Cgas ...